FAK and paxillin, two potential targets in pancreatic cancer

Citations Over TimeTop 10% of 2016 papers

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer in large part due to late diagnosis and a lack of effective screening tests. In spite of recent progress in imaging, surgery and new therapeutic options for pancreatic cancer, the overall five-year survival still remains unacceptably low. Numerous studies have shown that focal adhesion kinase (FAK) is activated in many cancers including PDAC and promotes cancer progression and metastasis. Paxillin, an intracellular adaptor protein that plays a key role in cytoskeletal organization, connects integrins to FAK and plays a key role in assembly and disassembly of focal adhesions. Here, we have reviewed evidence in support of FAK as a potential therapeutic target and summarized related combinatorial therapies.

Related Papers

• → Endothelial paxillin and focal adhesion kinase (FAK) play a critical role in neutrophil transmigration(2011)45 cited
• → Lack of Paxillin phosphorylation promotes single-cell migration in vivo(2023)22 cited
• → Paxillin Binding Is Not the Sole Determinant of Focal Adhesion Localization or Dominant-Negative Activity of Focal Adhesion Kinase/Focal Adhesion Kinase-related Nonkinase(2000)62 cited
• → Specific decrease in the level of Hic-5, a focal adhesion protein, during immortalization of mouse embryonic fibroblasts, and its association with focal adhesion kinase(2000)34 cited
• Expressions of focal adhesion kinase and paxillin in human scar tissues(2006)